Changing Treatment Landscape for Follicular Lymphoma

News
Video

This video examines the evolution in treatment and survival outcomes for patients with follicular lymphoma and highlights trials testing newer agents such as immunotherapies in this population.

In this video, Nathan H. Fowler, MD, of MD Anderson Cancer Center, discusses the evolution in treatment for patients with follicular lymphoma and the improvement in survival outcomes since the introduction of the monoclonal antibody rituximab in this setting.

Dr. Fowler also reviews the standard treatment for these patients, the role of novel antibodies following chemotherapy failure, and looks ahead at newer agents such as checkpoint inhibitors and chimeric antigen receptor (CAR) T-cell therapy currently in trials for follicular lymphoma.

Recent Videos
Certain bridging therapies and abundant steroid use may complicate the T-cell collection process during CAR T therapy.
Educating community practices on CAR T referral and sequencing treatment strategies may help increase CAR T utilization.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
The addition of radiotherapy to CAR T-cell therapy may particularly benefit patients with localized disease, according to Timothy Robinson, MD, PhD.
Timothy Robinson, MD, PhD, discusses how radiation may play a role as bridging therapy to CAR T-cell therapy for patients with relapsed/refractory DLBCL.
Pallawi Torka, MD, with the Oncology Brothers presenting slides
Related Content
Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL

Real-World Results May Differ From Clinical Trials of CAR T-Cell Therapy Use in DLBCL

Kristie L. Kahl
November 17th 2024
Article

“When thinking about treatment options for refractory DLBCL you consider: Is it safe to give an older patient CAR T-[cell therapy]?,” said Jennifer Amengual, MD.

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Collaboration Fosters Treatment Advancements for Young Lymphoma Populations

Andrew M. Evens, DO, MS
November 18th 2024
Podcast

A leader from the adolescent and young adult lymphoma space discusses how collaboration between adult and pediatric oncologists has transformed the field.

Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

Improving Disease Modification and Immune Responses in Myelofibrosis With Pelabresib

ONCOLOGY Staff
November 16th 2024
Article

David M. Swoboda, MD, and Andrew Kuykendall, MD, spoke about the current treatment strategies and potential advancements that may improve outcomes such as spleen volume reduction in the myelofibrosis field.

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

Leveraging Ex Vivo Gene Therapy Advancements in Hemoglobinopathies and Metabolic Diseases

Alexis K. Kuhn, PharmD, BCOP ;Katie Bruce, PharmD, BCPPS;Susie Long, PharmD
October 21st 2024
Podcast

A panel of expert pharmacists provides their perspectives on gene therapy agents such as exagamglogene autotemcel in the management of sickle cell disease.

3 Things You Should Know About Biomarkers in DLBCL

3 Things You Should Know About Biomarkers in DLBCL

Matthew A. Lunning, MD;Sarah C. Rutherford, MD
November 11th 2024
Article

DLBCL is a genetically heterogeneous malignancy with multiple subtypes and recent investigations based on molecular profiles have opened the possibility for personalized therapy in this disease space.

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.

Valemetostat Yields Enduring Responses in Relapsed/Refractory PTCL

Russ Conroy
November 6th 2024
Article

Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.